Astrazeneca PLC
- AZN
- NYSE
- Consumer Products
- Latest 51.71
- Currency US$
- Change 0.21
- Percent Change 0.408 %
- Volume 1,774,081
- Tue May 21, 2013 4:00 PM EDT NYSE data delayed 15 minutes.
The Globe and Mail
- Open 51.12
- Previous Close 51.50
- High 51.79
- Low 51.00
- Bidx0 50.76
- Askx0 52.49
- 52-week High -- 52.27
- 52-week Low -- 39.72
- Beta 0.571
- Market Cap 64,482.37M
- EPS 4.51
- P/E 11.47
- Forward P/E 10.219
- PEG --
- Annual Dividend 3.80
- Yield 7.349
News
- Results from Phase III Studies of Naloxegol for Treatment of Opioid-Induced Constipation Presented at Digestive Disease Week 2013
- Assessing Your Asthma is Key to Taking Control
- Sub-Group Analysis Shows Investigational Metreleptin Treatment Demonstrated Reductions in HbA1c, Triglycerides and Liver Function Tests in Pediatric Patients with Lipodystrophy During a 12-Month Period
- AstraZeneca to Establish Strategic R&D Center in Gaithersburg, Md; Wilmington Remains North America Commercial Headquarters
- AstraZeneca Encourages Atherosclerosis Education among High Risk Patients during American Heart Month
Financials & Calendars
- Sales $27,009,000,000
- Earnings $5,668,000,000
- Return on Equity 24.41%
- Cash Flow --
- Cash $7,146,000,000
- Current Ratio 1.32
12 months ended Mar 31, 2013.
Trailing 12 month results shown above.
All data is in U.S. dollars.
- Assets $52,329,000,000
- Liabilities $29,841,000,000
- Liabilities-to-Equity Ratio 1.33
Price Ratios
- Price to Sales 2.39
- Price to Book 2.87
- Price to Cash Flow n/a
Event Calendar
| Event | Last | Next | ||
|---|---|---|---|---|
| Earnings | Apr 25 | $1.34 | Jul 25 | $1.27 |
| Surprises | Apr 25 | 5.22% | n/a | n/a |
| Dividends | Feb 13 | $1.90 | n/a | n/a |
| Splits | n/a | -- | n/a | n/a |
12 months ended May 22, 2013.
A look at major corporate events and financial announcements that are coming up.
Company Information
About the Company
AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development, manufacture and marketing of ethical (prescription) pharmaceuticals and agricultural products, and the supply of healthcare services.
Officers
- Louis Schweitzer Chairman and Chairman of the N
- David Brennan Chief Executive Officer;Execut
- Company Type: n/a
- Company Status: n/a
- Full-time Employees: n/a
-
Incorporation:
United States,
n/a -
Top 1000 Ranking:
Profit: n/a
Revenue: n/a
Assets: n/a
Ideas & Discussion
Live Discussion of AZN on StockTwits